Lilly sells R&D campus to Covance in the pioneering deal.

-

Lilly sells R&D campus to Covance in the pioneering deal..


Yesterday, Eli Lilly made a significant step toward outsourcing with the sale of a significant R&D site to contract research group Covance and the formation of new contracts with Quintiles and i3. 


Lilly is adopting a road that is less usual in R&D but is already well-trodden in the pharmaceutical manufacturing industry. When faced with excess capacity, several pharmaceutical companies chose to sell off operations, frequently including legacy contracts, to management buyout teams or reputable contract manufacturers.

The Lilly/Covance deal is one of the first large-scale examples of this type of facility sale in early-stage drug development – a function that until recently was jealously guarded within the walls of big pharma companies. 

According to the terms of the agreement, Covance will offer jobs to 260 Lilly employees who work in non-Good Laboratory Practice (GLP) toxicology, in vivo pharmacology, quality control laboratory, and imaging services. Covance said it plans to upgrade the site and will "double or even triple" the workforce.

Comments

Post a Comment

Popular posts from this blog

 Role of Blockchain in Healthcare Data Management

-
Image
ROLE OF BLOCKCHAIN IN HEALTHCARE DATA MANAGEMENT I n recent years, the healthcare industry has been undergoing a digital transformation, leveraging innovative technologies to improve patient care and data management.   One such technology that has gained significant attention is blockchain. Originally known for powering cryptocurrencies like Bitcoin, blockchain has found a remarkable application in healthcare data management.  This decentralized and secure ledger system holds immense potential to revolutionize the way sensitive medical information is stored, shared, and utilized across the healthcare ecosystem.  What is  Role of Blockchain in Healthcare Data Management? Blockchain technology has the potential to  revolutionize healthcare data management. It is a type of distributed ledger technology (DLT)  that leverages decentralized peer-to-peer computing, cryptography, and related technology to verify and propagate a chain of transaction records across a consortium, alliance, part
Read more

Demystifying AI in Drug Discovery: Transforming Pharma R&D

-
Image
Demystifying AI in Drug Discovery: Transforming Pharma R&D Artificial Intelligence (AI) has swiftly transformed industries, and drug discovery is no exception.  The pharmaceutical research and development (R&D) process has traditionally been lengthy, resource-intensive, and marked by high failure rates. However, with the advent of AI, a new era has dawned, promising to revolutionize the drug discovery landscape.  This article delves into the nuances of AI in drug discovery , exploring how it's reshaping pharma R&D processes and accelerating the journey toward innovative therapies. 1. Understanding AI in Drug Discovery: AI refers to the simulation of human intelligence in machines, enabling them to perform tasks that typically require human cognition, such as learning, reasoning, and problem-solving.  In drug discovery, AI algorithms analyze vast datasets to identify patterns, predict outcomes, and generate insights that aid in the identification and development of poten
Read more